Socioeconomic and nutritional profile and cardiometabolic risk factors of schizophrenic patients treated with antipsychotics: a reflection for nutritional intervention
DOI:
https://doi.org/10.5020/18061230.2016.p60Keywords:
Schizophrenia, Antipsychotic Agents, Health Profile.Abstract
Objective: To characterize the socioeconomic and nutritional profile and cardiometabolic risk factors of patients with schizophrenia treated with antipsychotics at a public hospital in Fortaleza, Ceará. Methods: Quantitative descriptive cross-sectional study of 146 individuals with schizophrenia treated with antipsychotics in a tertiary health care facility in Fortaleza, Ceará. Data were collected in August and September 2012. Sociodemographic interviews and assessment of antipsychotics, clinical examination and anthropometric measurements (weight, height and waist, hip and abdominal circumferences) were carried out. Results: Among the respondents, 44.52% (n=65) were women and 55.48% (n=81) were men. The majority were 20-39 years old, white (n=47; 32,19%), single (n=117; 80.14%), had 1-9 years of education (n=51; 34.93%), were unemployed (n=110; 75.34%) and had an income of up to 1 wage (n=72; 49.32%). According to BMI classification, 25.34% were overweight (n=37) and 28.08% (n=41) were obese. A total of 78.32% of men (n=65) and 92.06% of women (n=58) were at very high risk of cardiovascular disease. In all, 51.22% of men (n=42) and 67.19% (n=43) of women were at risk of developing metabolic diseases. Conclusion: The study showed that most patients were in the productive period of life, were unemployed and had low income. It can be inferred that the majority were overweight and were more likely to develop metabolic disorders.Downloads
References
Rahmoune H, Harris LW, Guest PC, Bahn S. Explorando o componente inflamatório da esquizofrenia. Rev Psiquiatr Clín (São Paulo, Online). 2013;40(1):28-34.
World Health Organization - Who – Schizophrenia [acesso em 2015 Jul 2]. Disponível em: http://www. who.int/mental_health/management/schizophrenia/en/
Vaskinn A, Antonsen BT, Fretland RA, Dziobek I, Sundet K, Wilberg T. Theory of mind in women with borderline personality disorder or schizophrenia: differences in overall ability and error patterns. Front Psychol. 2015;6:1239.
Saloojee S, Burns JK, Motala AA. Metabolic Syndrome in South African Patients with Severe Mental Illness:Prevalence and Associated Risk Factors. Plos One. 2016;11(2):e0149209.
Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci. 2015;9(297):1-7.
Lopuszańska UJ, Skórzyńska-Dziduszko K, Lupa- Zatwarnicka K, Makara-Studzińska M. Mental illness and metabolic syndrome: a literature review. Ann Agric Environ Med. 2014;21(4):815-21.
Shulman M, Miller A, Misher J, Tentler A. Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach. J Multidiscip Healthc. 2014;7:489-501.
Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-96.
Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62(2):92-100.
Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27-35.
Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. 2001;24(1):59-73.
Leitão-Azevedo CL, Guimarães LR, Abreu MGB, Gama CS, Lobato MI, Belmonte-de-Abreu PS. Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics. Rev Bras Psiquiatr. 2006;28(4):301-4.
Connolly M, Kelly C. Lifestyle and physical health in schizophrenia. Adv Psychiatr Treat. 2005;11(2):125-32.
Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115-21.
Ministério da Saúde (BR), Secretaria de Atenção à Saúde, Departamento de Atenção Básica. Estratégias para o cuidado da pessoa com doença crônica: obesidade. Brasília: Ministério da Saúde; 2014.
World Health Organization. Preventing and managing the global epidemic of obesity. Geneva: WHO; 1997. [Report of the World Health Organization Consultation of Obesity]
Ministério da Saúde (BR). Vigilância alimentar e nutricional SISVAN. Brasília: Editora Brasil; 2004.
Tomasi E, Nunes BP, Thumé E, Silveira DS, Siqueira FV, Piccini RX et al . Utilização de serviços de saúde no Brasil: associação com indicadores de excesso de peso e gordura abdominal. Cad Saúde Pública. 2014;30(7):1515-24.
Conselho Nacional de Saúde (BR). Resolução Nº 196/96. Estabelece critérios sobre pesquisa envolvendo seres humanos. Bioética. 1996;4(2):15-25.
Medeiros EN. Prevalência dos transtornos mentais e perfil socioeconômico dos usuários atendidos nos serviços de saúde dos municípios paraibanos [dissertação]. João Pessoa: Centro e Ciências da Saúde da UFP; 2005.
Mari JJ, Leitão RJ. A epidemiologia da esquizofrenia. Rev Bras Psiquiatr. 2000;22(Supl 1):15-17.
Rabelo AR, Cardoso E, Melo A. Características sociodemográficas da população psiquiátrica internada nos hospitais do sistema único de saúde do estado da Bahia. Rev Baiana Saúde Pública. 2005;29(1):43-56.
Costa SAJ, Andrade FVK. Perfil dos usuários incluídos no protocolo de esquizofrenia em um programa de medicamentos do componente especializado da assistência farmacêutica. Rev Baiana Saúde Pública. 2011;35(2):446-56.
Santana AFFA, Chianca TCM, Cardoso SC. Qualidade de vida de pacientes com esquizofrenia internados em hospital de custódia. J Bras Psiquiatr. 2009;58(3):187-94.
Junqueira SAE. Perfil sociodemográfico e clínico de pacientes psiquiátricos tratados em Hospital Dia [dissertação]. Ribeirão Preto: Faculdade de Medicina de Ribeirão Preto/ Universidade de São Paulo, Ribeirão Preto; 2009.
Instituto de Pesquisa Econômica Aplicada - IPEA. PNAD mostra aumento da escolaridade média do brasileiro [acessado 2014 Mar 23]. Disponível em: http://www.ipea.gov.br/portal/index.php?option=com_content&view=article&id=20012
Rede Record Notícias. Trabalhador ganha salário médio de R$ 1.792 no País, diz IBGE [acessado 2014 Mar 23]. Disponível em: http://noticias.r7.com/empregos/noticias/trabalhador-ganha-salario-medio-de-r-1-792- no-pais-diz-ibge-20130524.html.
Cerqueira EA Filho, Arandas FS, Oliveira IR, Sena EP. Dislipidemias e antipsicóticos atípicos. J Bras Psiquiatr. 2006;55(4):296-307.
Leitão-Azevedo CL, Guimarães LR, Lobato MI, et al. Ganho de peso e alterações metabólicas em esquizofrenia. Rev Psiquiatr Clin. 2007;34(Supl 2):184-8.
Sweeting J, Duflou J, Semsarian C. Postmortem analysis of cardiovascular deaths in schizophrenia: a 10-year review. Schizophr Res. 2013;150(2-3):398-403.
Bray, GA. Classification and evolution of the obesities. Med Clin North Am. 1989;73(1):161-84.
Meyer J, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract. 2006;12(1):5-10.
Elkis H, Gama C, Suplicy H, Tambascia M, Bressan R, Lyra R et al. Consenso brasileiro sobre antipsicóticos de segunda geração e distúrbios metabólicos. Rev Bras Psiquiatr. 2008;30(1):77-85.
Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65(Suppl18):13-26.
Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand. 2003;108(5):324-32.
Vargas TS, Santos ZEA. Prevalência de síndrome metabólica em pacientes com esquizofrenia. Sci Med. 2011;21(1):4-8.
Cai J, Yi Z, Lu W, Fang Y, Zhang C. Crosstalk between 5-HT2cR and PTEN signaling pathway in atypical antipsychotic-induced metabolic syndrome and cognitive dysfunction. Med Hypotheses. 2013;80(4):486-9.
Said MA, Hatim A, Habil MH, Zafidah W, Haslina MY, Badiah Y, Ramli et al. Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia. Prev Med. 2013; 57(Suppl):S50-3.
Prisco V, Perris F, Santis T, Palermito A, Catapano F, Fabrazzo M. Metabolic syndrome and antipsychotic treatment: How about schizophrenia and bipolar disorder? Eur Psychiatry. 2013; 28(Suppl1):1.
Manu P, Correll CU, Wampers M, Winkel RV, Yu W, Shiffeldrim D et al. Dysmetabolic features of the overweight patients receiving antipsychoticdrugs: a comparison with normal weight and obese subjects. Eur Psychiatry. 2014;29(3):179-82.
Teixeira PJR, Rocha FL. Associação entre síndrome metabólica e transtorno mental. Rev Psiquiatr Clín (São Paulo). 2007;34(5):28-38.
Roeder MA. Atividade física, saúde mental e qualidade de vida. 27ª ed. Rio de Janeiro: Shape; 2003
